Royalty pharma plc RPRX 深 滬
等待開盤 09-08 09:30:00 美东时间
63.96
+0.080
+0.13%
華盛通- 最 高64.38
- 今 開63.55
- 成交量 340.26万股
- 最 低 63.43
- 昨 收 63.88
- 總市值 367.77亿
- 52周最高 64.38
- 市盈率 靜 35.90
- 換手率 0.59%
- 52周最低 33.705
- 委 比 -64.45%
- 總股本 5.75亿
- 歷史最高 64.38
- 量 比 1.20
- 振 幅 1.49%
- 歷史最低 22.465
- 每 手 1
- 風險率 8.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM...
5分钟前
美股夜盘 | 英特尔升逾3%，公司暂定10月上旬再涨价10%；Bloom Energy升逾7%，获纳入标普500指数；存储股盘前齐涨，闪迪升逾4%
英特尔升逾3%，公司暂定10月上旬再涨价10%；Bloom Energy升逾7%，获纳入标普500指数；存储股盘前齐涨，闪迪升逾4%，美光科技、SK海力士升逾2%
今天 08:10
Teva launches offering of senior notes to refinance existing debt
Teva Pharmaceutical Industries (TEVA) to issue euro- and dollar-denominated senior notes through its finance subsidiaries, with proceeds primarily intended to refinance existing debt. The company inte...
09-07 16:57
美股盘后 | Bloom Energy大升6.22%，HubSpot上升3.74%
Bloom Energy大升6.22%；HubSpot上升3.74%；Everpure上升2.20%
09-05 06:11
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Royalty Pharma plc announced that Novartis' Phase 3 HORIZON trial for pelacarsen, an antisense oligonucleotide for atherosclerotic cardiovascular disease and elevated Lp(a), failed to meet its primary endpoint of reducing cardiovascular events. Despite this, Royalty Pharma expects to recover its $500 million investment in Ionis through Spinraza royalties, with a modest positive return. The company reaffirms its 2030 Portfolio Receipts target of $...
09-04 23:05
